Saw XRTX stocks jump over 40% overnight and had to dig into what happened. Turns out they're extending their deal to acquire this renal anti-fibrotic program from Vectus Biosystems - VB4-P5 is the compound they're after, still in pre-IND stage but targeting kidney diseases which is a pretty big market. The original deal was supposed to close by end of Q1 but they just amended it to March 31, 2026 to sort out the IP transfer stuff.

They originally announced the binding term sheet back in October 2025 for $3 million in stock consideration. What's interesting is this pharma company has a whole pipeline going - they've got XRx-026 for gout in clinical trials, XRx-008 for ADPKD, and some other programs in development. The stocks were trading at $0.49 before this news dropped, so that 40% move to $0.68 is pretty significant for a small-cap biotech.

They're also holding their annual shareholder meeting on March 24, 2026. I'm curious if this acquisition is the kind of thing that actually moves the needle for them or if it's just noise. Anyone else watching these biotech stocks lately?